Cyanide

Cyanide

SCHEMBL1993368

C#N.CCC(N)(CC)CC

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44443 0.88
Water SCHEMBL188611 0.84
Bromide SCHEMBL1566336 0.84
Iodide SCHEMBL1567793 0.84
Fluoride SCHEMBL191143 0.84
Hydrochloric Acid SCHEMBL659839 0.84
Ammonia Solution, Strong SCHEMBL3400813 0.84
Fluoride SCHEMBL4584812 0.80 TSHR (0.33) TSHRTDP1
Fluoride SCHEMBL5067814 0.80 TSHR (0.33) TSHRTDP1
Cyanamide SCHEMBL4951615 0.79 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10559852-B2 Electrolyte solution for lithium secondary battery and lithium secondary battery having same SAMSUNG SDI CO., LTD. (KR) 2020-02-11 US claimed
CN-107251309-B Electrolyte solution for lithium secondary battery and lithium secondary battery having the same 三星SDI株式会社 2019-12-06 CN claimed
EP-3240091-B1 ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY HAVING SAME SAMSUNG SDI CO LTD (KR) 2019-09-11 EP claimed
US-20180026307-A1 ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY HAVING SAME SAMSUNG SDI CO., LTD. (KR) 2018-01-25 US claimed
EP-3240091-A1 ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY HAVING SAME Samsung SDI Co., Ltd. (KR) 2017-11-01 EP claimed
US-10559852-B2 Electrolyte solution for lithium secondary battery and lithium secondary battery having same SAMSUNG SDI CO., LTD. (KR) 2020-02-11 US disclosed
CN-107251309-B Electrolyte solution for lithium secondary battery and lithium secondary battery having the same 三星SDI株式会社 2019-12-06 CN disclosed
EP-3240091-B1 ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY HAVING SAME SAMSUNG SDI CO LTD (KR) 2019-09-11 EP disclosed
US-20180026307-A1 ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY HAVING SAME SAMSUNG SDI CO., LTD. (KR) 2018-01-25 US disclosed
EP-3240091-A1 ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY HAVING SAME Samsung SDI Co., Ltd. (KR) 2017-11-01 EP disclosed
US-9243013-B2 Ionic compound, method for producing the same, and ion-conductive material comprising the same NIPPON SHOKUBAI CO., LTD. (JP) 2016-01-26 US disclosed
US-20110150736-A1 IONIC COMPOUND, METHOD FOR PRODUCING THE SAME, AND ION-CONDUCTIVE MATERIAL COMPRISING THE SAME NIPPON SHOKUBAI CO., LTD. (JP) 2011-06-23 US disclosed
EP-2327707-A1 IONIC COMPOUND, PROCESS FOR PRODUCING SAME, AND ION-CONDUCTIVE MATERIAL COMPRISING SAME Nippon Shokubai Co., Ltd. (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150736-A1 IONIC COMPOUND, METHOD FOR PRODUCING THE SAME, AND ION-CONDUCTIVE MATERIAL COMPRISING THE SAME KCNB1, KCNB2, KCNMB1 TSHR 2693/4885TDP1 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.